公开(公告)号：WO2006037660A3

公开(公告)日：2006-08-03

申请号：PCT/EP2005010885

申请日：2005-10-10

Applicant: DEUTSCHES KREBSFORSCH ,  WOLF STEPHAN ,  JOSS STEFAN ,  MERTENS DANIEL ,  PSCHERER ARMIN ,  LICHTER PETER

Inventor： WOLF STEPHAN ,  JOSS STEFAN ,  MERTENS DANIEL ,  PSCHERER ARMIN ,  LICHTER PETER

IPC: G01N33/48 ,  A61K39/395

CPC classification number: G01N33/57426 ,  G01N2333/715 ,  G01N2500/00

Abstract: Described are methods and compounds for diagnosis and therapy of subsets of cell proliferative disorders which are characterized by resistance to TRAIL induced apoptosis. Examples of such diseases are B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and prostate cancer. Furthermore, methods for identifying drugs which are suitable for treatment of such diseases are described.

Abstract translation: 描述了用于诊断和治疗以TRAIL诱导的细胞凋亡抗性为特征的细胞增殖性病症亚群的方法和化合物。 这些疾病的例子是B细胞慢性淋巴细胞性白血病（CLL），套细胞淋巴瘤（MCL）和前列腺癌。 此外，描述了鉴定适合于治疗这些疾病的药物的方法。

公开(公告)号：WO2005040418A3

公开(公告)日：2005-11-10

申请号：PCT/EP2004011269

申请日：2004-10-08

Applicant: DEUTSCHES KREBSFORSCH ,  NIEHRS CHRISTOF ,  WU WEI ,  GLINKA ANDREI ,  KAZANSKAYA OLGA

Inventor： NIEHRS CHRISTOF ,  WU WEI ,  GLINKA ANDREI ,  KAZANSKAYA OLGA

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/78 ,  C12Q1/68

CPC classification number: C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5041 ,  G01N33/574 ,  G01N33/57492 ,  G01N2500/10

Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(= R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.

Abstract translation: 本发明涉及可用于诊断与编码分泌蛋白质Futrin 1,2,3和/或4（= R-Spondin 2,3,3和1）的基因的异常表达有关的疾病的组合物， 例如 与肿瘤或肌肉，肾脏或骨骼的疾病有关。 本发明还涉及含有能够修饰（a）编码Futrin 1,2,3和/或4的基因的表达或（b）Futrin 1,2,3的活性的化合物的药物组合物 和/或4蛋白。

公开(公告)号：WO03078458A9

公开(公告)日：2005-03-03

申请号：PCT/EP0302831

申请日：2003-03-18

Applicant: DEUTSCHES KREBSFORSCH ,  ANGEL PETER ,  BREITENBACH UTE ,  RICHTER HARTMUT ,  HESS JOCHEN ,  TUCKERMANN JAN ,  FUERSTENBERGER GERHARD ,  PROFT VERENA

Inventor： ANGEL PETER ,  BREITENBACH UTE ,  RICHTER HARTMUT ,  HESS JOCHEN ,  TUCKERMANN JAN ,  FUERSTENBERGER GERHARD ,  PROFT VERENA

IPC: A61P35/00 ,  C07K14/47 ,  C12N1/19 ,  C12N1/21 ,  C12N9/64 ,  C12N15/12 ,  C12N15/57 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/48 ,  A61K48/00 ,  C12N5/10 ,  C12N15/62 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574

CPC classification number: C12N9/6478 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/4748 ,  C07K2319/00

Abstract: Described are a novel marker protein associated with apithelial tumors, TAP-70, belonging to the family of aspartyl proteinases and nucleic acid molecules encoding TAP-70 polypeptides. Moreover, diagnostic and therapeutic uses based on the finding that TAP-70 is overexpressed throughout skin carcinogenesis are described.

Abstract translation: 描述了与apithelial肿瘤TAP-70相关的新型标记蛋白，属于天冬氨酰蛋白酶家族和编码TAP-70多肽的核酸分子。 此外，描述了基于TAP-70在皮肤致癌过程中过表达的发现的诊断和治疗用途。

公开(公告)号：WO2004003008A2

公开(公告)日：2004-01-08

申请号：PCT/EP0306958

申请日：2003-07-01

Applicant: DEUTSCHES KREBSFORSCH ,  BUTZ KARIN ,  CRNKOVIC-MERTENS IRENA ,  HOPPE-SEYLER FELIX ,  RAUSCH CHRISTIAN

Inventor： BUTZ KARIN ,  CRNKOVIC-MERTENS IRENA ,  HOPPE-SEYLER FELIX ,  RAUSCH CHRISTIAN

IPC: A61K38/00 ,  C07K7/08 ,  C07K11/00 ,  C07K14/00 ,  C07K14/47

CPC classification number: C07K7/08 ,  A61K38/00 ,  C07K14/001 ,  C07K14/4747

Abstract: The present invention relates to peptides which interact with IAPs. IAPs are highly expressed in tumor cells which fail to undergo apoptosis. By binding to IAPs, the peptides of the present invention release tumor cells from the apoptosis block and thus provide a new tool for effective cancer therapy.

Abstract translation: 本发明涉及与IAP相互作用的肽。 IAP在不能进行细胞凋亡的肿瘤细胞中高度表达。 通过结合IAP，本发明的肽从凋亡阻断区释放肿瘤细胞，从而提供有效的癌症治疗的新工具。

公开(公告)号：WO0204952A3

公开(公告)日：2003-11-06

申请号：PCT/EP0107924

申请日：2001-07-10

Applicant: DEUTSCHES KREBSFORSCH ,  MOR RESEARCH APPLIC LTD ,  ALTEVOGT PETER ,  FOGEL MINA

Inventor： ALTEVOGT PETER ,  FOGEL MINA

IPC: G01N33/53 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/566 ,  G01N33/574 ,  A61K38/17 ,  A61K47/48 ,  G01N33/577 ,  G01N33/68

CPC classification number: G01N33/57449 ,  G01N33/57442 ,  G01N2333/70503 ,  G01N2333/70596

Abstract: A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.

Abstract translation: 描述了一种用于诊断卵巢或子宫内膜肿瘤或预后的方法，其特征在于在患者样品中优选通过抗L1抗体测定L1水平，L1的存在是存在 卵巢或子宫内膜肿瘤或这种肿瘤的倾向。 此外，提供了治疗卵巢或子宫内膜肿瘤的方法。

公开(公告)号：WO03059392A2

公开(公告)日：2003-07-24

申请号：PCT/DE0300124

申请日：2003-01-17

Applicant: DEUTSCHES KREBSFORSCH ,  BRAUN KLAUS ,  BRAUN ISABELL ,  DEBUS JUERGEN ,  PIPKORN RUEDIGER ,  WALDECK WALDEMAR

Inventor： BRAUN KLAUS ,  BRAUN ISABELL ,  DEBUS JUERGEN ,  PIPKORN RUEDIGER ,  WALDECK WALDEMAR

IPC: A61K47/48

CPC classification number: A61K47/50

Abstract: The invention relates to a conjugate for treating prokaryotic infections, consisting of a transport mediator that can penetrate the prokaryotic cell membrane and a desired compound that is to be introduced into the prokaryote and is directed against the latter. Said compound is preferably a peptide nucleic acid (PNA), which is directed against a gene of the prokaryote that imparts a resistance to antibiotics.

Abstract translation: 的缀合物用于从原核细胞膜治疗原核感染通过传输介体和所期望的那样，被引入原核生物和针对该化合物，其优选是其针对原核生物的基因的肽NukleinsäurePNA 赋予抗生素抗性。

公开(公告)号：WO0238803A3

公开(公告)日：2003-07-17

申请号：PCT/DE0104229

申请日：2001-11-08

Applicant: DEUTSCHES KREBSFORSCH ,  EICHMUELLER STEFAN ,  SCHADENDORF DIRK ,  USENER DIRK

Inventor： EICHMUELLER STEFAN ,  SCHADENDORF DIRK ,  USENER DIRK

IPC: A61K39/00 ,  A61P35/00 ,  C07H21/00 ,  C07K14/435 ,  C07K14/47 ,  C07K16/00 ,  C07K16/30 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: The invention relates to a novel marker for tumours, preferably CTCL. The invention further relates to the application of the above for the diagnosis and therapy of tumour-related diseases, preferably CTCL.

Abstract translation: 本发明涉及新的标志物的肿瘤，优选CTCL。 本发明还涉及它们用于肿瘤疾病，优选CTCL的诊断或治疗中的用途。

公开(公告)号：WO02057433A3

公开(公告)日：2003-05-01

申请号：PCT/EP0200557

申请日：2002-01-21

Applicant: DEUTSCHES KREBSFORSCH ,  HOFMANN THOMAS ,  SCHMITZ LIENHARD ,  DROEGE WULF ,  MOELLER ANDREAS ,  WILL HANS ,  HUESEYIN SIRMA

Inventor： HOFMANN THOMAS ,  SCHMITZ LIENHARD ,  DROEGE WULF ,  MOELLER ANDREAS ,  WILL HANS ,  HUESEYIN SIRMA

IPC: C12N1/21 ,  C12N9/12 ,  C12N15/54 ,  C12N15/52 ,  A61K38/17

CPC classification number: C12N9/1205 ,  C07K2319/00

Abstract: The invention relates to the use of homeodomain-interacting protein kinases (HIPKs), especially HIPK2, and the nucleic acid sequences coding for the same, for influencing cell division and cell proliferation, and especially the use thereof in methods for diagnosing or treating diseases associated with anomalous or excessive cell proliferation e.g. tumour diseases. The invention also relates to the use of HIPKs, especially HIPK2, the nucleic acid sequences coding for the same and specific bonding partners thereof, for identifying and/or producing substances which can inhibit or stimulate cell division or cell growth or influence the same in other ways. The invention especially relates to a human HIPK2 and derivatives and fragments thereof, the nucleic acid sequences coding for the same, and antibodies and other specific bonding partners of the human HIPK2 and the nucleic acid sequence coding for the same.

Abstract translation: 本发明涉及使用HIPK激酶，特别是HIPK2激酶，以及编码在用于疾病与异常或过度的细胞增殖，例如相关联的诊断或治疗方法中的用途影响细胞分裂和细胞增殖，特别是核酸序列 的肿瘤疾病。 本发明还可以涉及使用HIPK激酶，特别是HIPK2激酶，以及核酸序列的编码和用于抑制物质的鉴别和/或产生特异性结合配偶体，刺激对其它方式的细胞分裂或细胞生长，或影响 ， 更具体地说，本发明涉及一种人的HIPK2激酶和衍生物和片段，所述的核酸序列编码，以及抗体和对于人HIPK2激酶其他特异性结合配偶体和编码核酸序列。

公开(公告)号：WO03013591A3

公开(公告)日：2003-04-17

申请号：PCT/EP0208927

申请日：2002-08-09

Applicant: DEUTSCHES KREBSFORSCH ,  HERR INGRID ,  DEBATIN KLAUS-MICHAEL

Inventor： HERR INGRID ,  DEBATIN KLAUS-MICHAEL

IPC: A61K38/48 ,  A61P35/00 ,  C12Q1/68 ,  G01N33/50

CPC classification number: A61K38/4873

Abstract: Described are pharmaceutical compositions containing a caspase-8 and/or caspase-9 protein and/or (a) DNA sequence(s) encoding a caspase-8 and/or caspase-9 protein and a suitable pharmaceutical carrier. Said compositions are useful for restoring apoptosis sensitivity of glucorticoid-induced resistance of carcinoma cells towards cytotoxic therapy.

Abstract translation: 描述了含有半胱天冬酶-8和/或半胱天冬酶-9蛋白和/或（a）编码半胱天冬酶-8和/或半胱天冬酶-9蛋白的DNA序列和合适的药物载体的药物组合物。 所述组合物可用于恢复糖皮质激素诱导的癌细胞对细胞毒性治疗的耐药性的细胞凋亡敏感性。

公开(公告)号：WO02057433A9

公开(公告)日：2002-10-31

申请号：PCT/EP0200557

申请日：2002-01-21

Applicant: DEUTSCHES KREBSFORSCH ,  HOFMANN THOMAS ,  SCHMITZ LIENHARD ,  DROEGE WULF ,  MOELLER ANDREAS ,  WILL HANS ,  HUESEYIN SIRMA

Inventor： HOFMANN THOMAS ,  SCHMITZ LIENHARD ,  DROEGE WULF ,  MOELLER ANDREAS ,  WILL HANS ,  HUESEYIN SIRMA

IPC: C12N1/21 ,  C12N9/12 ,  C12N15/54

CPC classification number: C12N9/1205 ,  C07K2319/00

Abstract: The invention relates to the use of homeodomain-interacting protein kinases (HIPKs), especially HIPK2, and the nucleic acid sequences coding for the same, for influencing cell division and cell proliferation, and especially the use thereof in methods for diagnosing or treating diseases associated with anomalous or excessive cell proliferation e.g. tumour diseases. The invention also relates to the use of HIPKs, especially HIPK2, the nucleic acid sequences coding for the same and specific bonding partners thereof, for identifying and/or producing substances which can inhibit or stimulate cell division or cell growth or influence the same in other ways. The invention especially relates to a human HIPK2 and derivatives and fragments thereof, the nucleic acid sequences coding for the same, and antibodies and other specific bonding partners of the human HIPK2 and the nucleic acid sequence coding for the same.

Abstract translation: 本发明涉及使用HIPK激酶，特别是HIPK2激酶，以及编码在用于疾病与异常或过度的细胞增殖，例如相关联的诊断或治疗方法中的用途影响细胞分裂和细胞增殖，特别是核酸序列 的肿瘤疾病。 本发明还可以涉及使用HIPK激酶，特别是HIPK2激酶，以及核酸序列的编码和用于抑制物质的鉴别和/或产生特异性结合配偶体，刺激对其它方式的细胞分裂或细胞生长，或影响 ， 更具体地说，本发明涉及一种人的HIPK2激酶和衍生物和片段，所述的核酸序列编码，以及抗体和对于人HIPK2激酶其他特异性结合配偶体和编码核酸序列。